Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELU Celularity	$2.19 -3.9%	$1.77	$1.00 ▼ $5.22	$52.45M	0.61	333,472 shs	24,660 shs
DSGN Design Therapeutics	$3.73 -7.0%	$3.68	$2.60 ▼ $7.77	$211.75M	1.77	184,629 shs	69,291 shs
MNPR Monopar Therapeutics	$32.07 -1.0%	$37.30	$1.72 ▼ $54.30	$196.11M	1.11	359,618 shs	17,074 shs
SLDB Solid Biosciences	$3.20 -3.0%	$3.12	$2.41 ▼ $10.37	$248.05M	2.32	1.08 million shs	868,844 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELU Celularity	0.00%	-4.37%	+37.30%	+87.18%	-29.58%
DSGN Design Therapeutics	0.00%	-2.10%	-19.78%	-17.48%	-7.90%
MNPR Monopar Therapeutics	0.00%	-9.53%	-28.67%	+3.69%	+949.58%
SLDB Solid Biosciences	0.00%	+13.88%	-25.75%	-37.50%	-61.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CELU Celularity	0.1773 of 5 stars	0.0	1.0	2.1	1.7	0.0
DSGN Design Therapeutics	0.5017 of 5 stars	1.0	0.0	2.9	2.5	0.6
MNPR Monopar Therapeutics	3.0403 of 5 stars	3.4	5.0	3.0	2.5	0.0
SLDB Solid Biosciences	3.921 of 5 stars	4.6	1.0	2.9	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELU Celularity	0.00	N/A	N/A	N/A
DSGN Design Therapeutics	2.00	Hold	$4.00	7.24% Upside
MNPR Monopar Therapeutics	2.75	Moderate Buy	$55.33	72.54% Upside
SLDB Solid Biosciences	3.23	Buy	$14.90	365.63% Upside

Current Analyst Ratings Breakdown

Latest CELU, SLDB, MNPR, and DSGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$16.00
5/19/2025	SLDB Solid Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/16/2025	SLDB Solid Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$20.00 ➝ $17.00
5/16/2025	SLDB Solid Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$15.00 ➝ $10.00
5/16/2025	SLDB Solid Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$18.00 ➝ $17.00
5/13/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/2/2025	MNPR Monopar Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/1/2025	MNPR Monopar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
3/19/2025	MNPR Monopar Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$76.00
3/13/2025	SLDB Solid Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.00 ➝ $11.00
3/10/2025	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$16.00 ➝ $20.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELU Celularity	$54.22M	0.97	$9.13 per share	0.24	$2.11 per share	1.04
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$4.96 per share	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$1.88 per share	N/A
SLDB Solid Biosciences	$8.09M	30.66	N/A	N/A	$6.27 per share	0.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELU Celularity	-$196.29M	-$2.65	N/A	∞	N/A	-72.72%	-119.53%	-25.40%	7/28/2025 (Estimated)
DSGN Design Therapeutics	-$66.86M	-$0.99	N/A	N/A	N/A	N/A	-18.01%	-17.38%	8/4/2025 (Estimated)
MNPR Monopar Therapeutics	-$8.40M	-$3.48	N/A	N/A	N/A	N/A	-107.21%	-87.57%	8/8/2025 (Estimated)
SLDB Solid Biosciences	-$96.01M	-$2.99	N/A	N/A	N/A	N/A	-58.75%	-47.84%	8/12/2025 (Estimated)

Latest CELU, SLDB, MNPR, and DSGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A
5/14/2025	Q1 2025	DSGN Design Therapeutics	-$0.28	-$0.31	-$0.03	-$0.31	N/A	N/A
5/13/2025	Q1 2025	MNPR Monopar Therapeutics	-$0.65	-$0.38	+$0.27	-$0.38	N/A	N/A
5/8/2025	Q4 2024	CELU Celularity	-$1.50	-$0.59	+$0.91	-$0.59	$5.20 million	$18.13 million
3/31/2025	Q4 2024	MNPR Monopar Therapeutics	-$0.36	-$2.23	-$1.87	-$2.23	N/A	N/A
3/10/2025	Q4 2024	DSGN Design Therapeutics	-$0.28	-$0.24	+$0.04	-$0.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELU Celularity	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELU Celularity	N/A	0.19	0.14
DSGN Design Therapeutics	N/A	34.61	34.61
MNPR Monopar Therapeutics	N/A	5.41	5.41
SLDB Solid Biosciences	N/A	7.85	7.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELU Celularity	19.02%
DSGN Design Therapeutics	56.64%
MNPR Monopar Therapeutics	1.83%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
CELU Celularity	22.10%
DSGN Design Therapeutics	31.20%
MNPR Monopar Therapeutics	20.50%
SLDB Solid Biosciences	13.63%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELU Celularity	220	23.95 million	18.55 million	Optionable
DSGN Design Therapeutics	40	56.77 million	38.96 million	Optionable
MNPR Monopar Therapeutics	10	6.12 million	3.97 million	Not Optionable
SLDB Solid Biosciences	100	77.52 million	35.05 million	Optionable

CELU, SLDB, MNPR, and DSGN Headlines

Recent News About These Companies

Millennium Management LLC Sells 397,321 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)

June 1 at 3:43 AM | marketbeat.com

Solid Biosciences’ SWOT analysis: gene therapy stock poised for potential breakthrough

May 28, 2025 | investing.com

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of "Buy" by Brokerages

May 28, 2025 | marketbeat.com

Research Analysts Set Expectations for SLDB FY2025 Earnings

May 27, 2025 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Earns "Overweight" Rating from Cantor Fitzgerald

May 24, 2025 | marketbeat.com

Chardan Capital Has Lowered Expectations for Solid Biosciences (NASDAQ:SLDB) Stock Price

May 21, 2025 | marketbeat.com

Q1 Earnings Forecast for SLDB Issued By William Blair

May 21, 2025 | marketbeat.com

Truist maintains buy on Solid Biosciences stock, price target at $16

May 18, 2025 | investing.com

Dimensional Fund Advisors LP Purchases 192,714 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)

May 18, 2025 | marketbeat.com

When Might Solid Biosciences Run Out Of Money?

May 17, 2025 | finance.yahoo.com

Solid Biosciences (NASDAQ:SLDB) Upgraded by Cantor Fitzgerald to "Strong-Buy" Rating

May 17, 2025 | marketbeat.com

Solid Biosciences Inc.: Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

May 16, 2025 | finanznachrichten.de

Solid Biosciences (SLDB) Expected to Announce Earnings on Wednesday

May 16, 2025 | marketbeat.com

Solid Biosciences files for $400M mixed securities shelf offering

May 16, 2025 | msn.com

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

May 15, 2025 | globenewswire.com

Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Rating of "Buy" by Brokerages

May 4, 2025 | marketbeat.com

Why Solid Biosciences Inc.’s (SLDB) Stock Is Up 10.82%

May 3, 2025 | aaii.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2025 | globenewswire.com

Solid Biosciences to Present Phase 1/2 Trial Data for SGT-003 Gene Therapy at ASGCT 2025 Annual Meeting

May 1, 2025 | nasdaq.com

Solid Biosciences to Participate at The Citizens Life Sciences Conference

April 30, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU, SLDB, MNPR, and DSGN Company Descriptions

Celularity NASDAQ:CELU

$2.19 -0.09 (-3.95%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$2.11 -0.08 (-3.65%)

As of 04:01 AM Eastern

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Design Therapeutics NASDAQ:DSGN

$3.73 -0.28 (-6.98%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$3.73 0.00 (0.00%)

As of 03:59 AM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Monopar Therapeutics NASDAQ:MNPR

$32.07 -0.32 (-0.99%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$31.73 -0.34 (-1.06%)

As of 04:00 AM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Solid Biosciences NASDAQ:SLDB

$3.20 -0.10 (-3.03%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$3.21 +0.01 (+0.31%)

As of 03:59 AM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time